Literature DB >> 19473751

A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease.

Alessandro Palmieri1, Ciro Imbimbo, Nicola Longo, Ferdinando Fusco, Paolo Verze, Francesco Mangiapia, Massimiliano Creta, Vincenzo Mirone.   

Abstract

BACKGROUND: Extracorporeal shock wave therapy (ESWT) is a conservative therapy for patients with Peyronie's disease (PD).
OBJECTIVE: To investigate the effects of ESWT in patients with PD. DESIGN, SETTING, AND PARTICIPANTS: One hundred patients with a history of PD not >12 mo who had not had previous PD-related treatments were enrolled in a prospective, randomized, double-blind, placebo-controlled study. Patients were randomly allocated to either ESWT (n=50) or placebo (n=50). Erectile function (EF), pain during erection, plaque size, penile curvature, and quality of life (QoL) were assessed at baseline, at 12 wk, and at 24 wk follow-up. INTERVENTION: Four weekly treatment sessions were administered. Each ESWT session consisted of 2000 focused shock waves. For the placebo group, a nonfunctioning transducer was employed. MEASUREMENTS: EF was evaluated with the shortened version of the International Index of Erectile Function (IIEF-5), pain was evaluated with a visual analog scale (VAS; 0-10), plaque size was measured in cm(2), and penile curvature was measured in degrees. RESULTS AND LIMITATIONS: After 12 wk, mean VAS score, mean IIEF-5 score, and mean QoL score ameliorated significantly in patients receiving ESWT. Mean plaque size and mean curvature degree were unchanged in the ESWT group, while a slight increase was reported in the placebo group (p-value not significant vs baseline). After 24 wk, mean IIEF-5 score and mean QoL score were stable in the ESWT group, while mean VAS score was significantly lower when compared with baseline in both groups. Interestingly, after 24 wk, mean plaque size and mean curvature degree were significantly higher in the placebo group when compared with both baseline and ESWT values. The main limitations were that the QoL questionnaire was not validated, ED was not etiologically characterized, and inclusion criteria were restricted.
CONCLUSIONS: In patients with PD, ESWT leads to pain resolution and ameliorates both EF and QoL.

Entities:  

Mesh:

Year:  2009        PMID: 19473751     DOI: 10.1016/j.eururo.2009.05.012

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  44 in total

1.  Peyronie's Disease: Nonsurgical Therapy Options.

Authors:  Franklin E Kuehhas; Peter Weibl; Tosev Georgi; Nenad Djakovic; Ralf Herwig
Journal:  Rev Urol       Date:  2011

Review 2.  Extracorporeal shock wave therapy mechanisms in musculoskeletal regenerative medicine.

Authors:  Claudio Lopes Simplicio; Joseph Purita; William Murrell; Gabriel Silva Santos; Rafael Gonzales Dos Santos; José Fábio Santos Duarte Lana
Journal:  J Clin Orthop Trauma       Date:  2020-02-12

3.  PEYRONIE'S DISEASE: A REVIEW OF ETIOLOGY, DIAGNOSIS, AND MANAGEMENT.

Authors:  Aylin N Bilgutay; Alexander W Pastuszak
Journal:  Curr Sex Health Rep       Date:  2015-06-01

Review 4.  [Current therapeutic options for Peyronie's disease].

Authors:  A Hauptmann; T Diemer; W Weidner
Journal:  Urologe A       Date:  2013-10       Impact factor: 0.639

5.  Acoustic field characterization of the Duolith: measurements and modeling of a clinical shock wave therapy device.

Authors:  Camilo Perez; Hong Chen; Thomas J Matula; Maria Karzova; Vera A Khokhlova
Journal:  J Acoust Soc Am       Date:  2013-08       Impact factor: 1.840

Review 6.  Treatment of Peyronie's disease: 2012 update.

Authors:  Ege Can Serefoglu; Wayne J G Hellstrom
Journal:  Curr Urol Rep       Date:  2011-12       Impact factor: 3.092

7.  [Peyronie's disease: diagnostics and therapy].

Authors:  A Hauptmann; T Diemer; W Weidner
Journal:  Urologe A       Date:  2011-05       Impact factor: 0.639

Review 8.  Nonsurgical treatment options in Peyronie's Disease: 2016 update.

Authors:  Raidh A Talib; Mohammed Abdulkareem Ibrahim; Önder Cangüven
Journal:  Turk J Urol       Date:  2016-12

Review 9.  Contemporary Review of Peyronie's Disease Treatment.

Authors:  Edward Capoccia; Laurence A Levine
Journal:  Curr Urol Rep       Date:  2018-05-17       Impact factor: 3.092

10.  2018 Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature.

Authors:  Anthony J Bella; Jay C Lee; Ethan D Grober; Serge Carrier; Francois Benard; Gerald B Brock
Journal:  Can Urol Assoc J       Date:  2018-02-22       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.